×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Therapeutic: Valproic Acid Trial Failure in Progressive Supranuclear Pals
therapeutic
859 words
KG: Valproic Acid Trial Failure in Progressive Supranuclear Palsy
2026-03-21
kind:therapeutic
section:therapeutics
state:published
Contents
Valproic Acid Trial Failure in Progressive Supranuclear Palsy
💊
Therapeutic Info
Name
Valproic Acid Trial Failure in Progressive Supranuclear Palsy
Summary
Page for Valproic Acid Trial Failure in Progressive Supranuclear Palsy
Knowledge Graph
Related Hypotheses (6)
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.51
HDAC6 Activation as SCFA-Mediated Neuroprotective Mechanism
Score: 0.54
Astrocyte-Mediated Neuronal Epigenetic Rescue
Score: 0.48
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.67
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.65
Mitochondrial-Nuclear Epigenetic Cross-Talk Restoration
Score: 0.45
Show 1 more
Related Analyses (21)
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Do tau strains or regional cellular environments primarily d
neurodegeneration · failed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Epigenetic reprogramming in aging neurons
neurodegeneration · archived
Cell type vulnerability in Alzheimers Disease (SEA-AD transc
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Astrocyte Reactivity Subtypes in Neurodegeneration
neurodegeneration · archived
GBA-Synuclein Loop: Therapeutic Strategies for Parkinson's D
neurodegeneration · completed
Gut-Brain Axis Therapeutics for Alzheimer's Disease
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · completed
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · archived
Show 16 more
Related Experiments (30)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
Show 25 more